Kamada (KMDA) Total Current Liabilities (2012 - 2026)
Kamada's (KMDA) quarterly Total Current Liabilities came in at $49.2 million in Q2 2026, up 7.4% on a YoY basis from $45.8 million in Q2 2025, and down 17.76% quarter-over-quarter from $59.8 million in Q1 2026.
Analysis
Kamada (KMDA) Total Current Liabilities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Total Current Liabilities for 13 consecutive years, with $49.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Current Liabilities rose 7.4% year-over-year to $49.2 million; the trailing twelve-month figure through Jun 2026 stood at $49.2 million (up 7.4% YoY), and the FY2025 full-year result was $47.4 million, down 4.04% from the prior year.
- Total Current Liabilities slipped to $49.2 million in Q2 2026 per KMDA's latest filing, from $59.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $75.7 million in Q4 2022 and bottomed at $34.0 million in Q3 2024.
- Historically, Total Current Liabilities has averaged $51.5 million across 5 years, with a median of $49.3 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities jumped 160.07% in 2022, then tumbled 46.34% in 2024.
- Over 5 years, Total Current Liabilities stood at $75.7 million in 2022, then sank by 34.49% to $49.6 million in 2023, then decreased by 0.41% to $49.4 million in 2024, then retreated by 4.04% to $47.4 million in 2025, then rose by 3.72% to $49.2 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $49.2 million, $59.8 million, and $47.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.39 Bn | 197.40 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 181.14 Bn | 177.96 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.91 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.36 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 54.39 Bn | 49.25 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 34.43 Bn | 31.12 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.18 Bn | 29.89 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Kamada | 472.70 Mn | 402.57 Mn | 22.47 Mn | 49.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.16 Mn |
| Mar 31, 2026 | 59.78 Mn |
| Dec 31, 2025 | 47.39 Mn |
| Sep 30, 2025 | 47.84 Mn |
| Jun 30, 2025 | 45.77 Mn |
| Mar 31, 2025 | 57.05 Mn |
| Dec 31, 2024 | 49.39 Mn |
| Sep 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 40.90 Mn |
| Mar 31, 2024 | 37.18 Mn |
| Dec 31, 2023 | 49.59 Mn |
| Sep 30, 2023 | 37.27 Mn |
| Jun 30, 2023 | 65.83 Mn |
| Mar 31, 2023 | 69.28 Mn |
| Dec 31, 2022 | 75.71 Mn |
| Sep 30, 2022 | 69.15 Mn |
| Jun 30, 2022 | 49.68 Mn |
| Mar 31, 2022 | 42.23 Mn |
| Dec 31, 2021 | 54.06 Mn |
| Sep 30, 2021 | 26.59 Mn |